by National Comprehensive Cancer Network New research in the June 2023 issue of Journal of the National Comprehensive Cancer Network has found that when alectinib—a safe and effective small molecule kinase inhibitor used to treat some types of advanced lung cancer—was taken with a fuller breakfast, or with lunch, it resulted in significantly higher drug concentrations than...
